• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

    10/28/24 8:00:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email

    – National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care –

    LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a partnership with GRAMMY Award-winning singer-songwriter, Carly Pearce, as part of its Life DisRPted campaign focused on promoting early diagnosis and treatment of recurrent pericarditis. Pearce announced that she had been diagnosed with the chronic autoinflammatory disease while on tour in May 2024.

    "We are excited to have Carly Pearce join our Life DisRPted campaign in support of the patients and caregivers facing recurrent pericarditis, a rare, chronic, flaring disease that is too often undertreated," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "With this campaign, we continue to provide a clear call to action for both patients and healthcare providers to seek out the signs of recurrent pericarditis and develop a treatment plan to minimize the impact it has on patient lives."

    To learn about recurrent pericarditis and the Life DisRPted campaign, visit LifeDisRPted.com.

    About Recurrent Pericarditis

    Recurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids.

    About Kiniksa

    Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

    About Carly Pearce

    Fiercely rooted in the classics, GRAMMY® Award-winning singer-songwriter Carly Pearce lit a fire with her debut album Every Little Thing and the PLATINUM-certified history-making title track, and she hasn't slowed down since. With the praised release of her highly anticipated fourth album, hummingbird (June 7, Big Machine Records), Pearce continues to resonate with her honest lyrics and timeless musicality. The critically acclaimed album includes lead single "we don't fight anymore" (featuring Chris Stapleton), which earned Pearce her second GRAMMY® nomination for Best Country Duo/Group Performance and fifth Top 5 Country Radio hit. Pearce is currently performing the new music on her headlining hummingbird world tour. Previously, her critically acclaimed and commercially lauded third studio album 29 produced Country Radio chart toppers including "Never Wanted To Be That Girl" with Ashley McBryde which gave Pearce her second consecutive ACM Music Event of the Year in 2022 and marked the third duet between two solo women to top Billboard's Country Airplay chart. The song also took home the 2022 CMA Musical Event of the Year and won a GRAMMY® Award for Best Country Duo/Group Performance, marking Pearce's first, and making history as the first female pairing to win in the category. In addition, Pearce's 3x PLATINUM-certified "I Hope You're Happy Now" with Lee Brice won both the 2020 CMA Awards Musical Event and 2021 ACM Awards Music Event, plus ACM Single of the Year. Both a Grand Ole Opry and Kentucky Music Hall of Fame member, Pearce has since made her 100th performance at the Grand Ole Opry. For more information, visit CarlyPearce.com.

    Every Second Counts! ®

    Kiniksa Investor Contact

    Jonathan Kirshenbaum

    (781) 829-3949

    [email protected]

    Kiniksa Media Contact

    Tyler Gagnon

    (781) 431-9100

    [email protected]

    Carly Pearce Media Contacts

    Erica Gerard

    [email protected]

    Avery Robinson

    [email protected]



    Primary Logo

    Get the next $KNSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What recent partnership did Kiniksa Pharmaceuticals enter into, and what is its purpose?

      Kiniksa Pharmaceuticals announced a partnership with Carly Pearce to promote the early diagnosis and treatment of recurrent pericarditis.

    • What is recurrent pericarditis and how does it affect patients?

      Recurrent pericarditis is a chronic autoinflammatory disease that causes pain and inflammation of the pericardium, which can lead to complications like pericardial effusion.

    • How many patients in the U.S. are affected by recurrent pericarditis annually?

      Approximately 40,000 patients in the U.S. seek treatment for recurrent pericarditis each year, with around 14,000 experiencing multiple recurrences.

    • When was Carly Pearce diagnosed with recurrent pericarditis, and how does she plan to raise awareness about this condition?

      Carly Pearce was diagnosed with recurrent pericarditis while on her tour in May 2024, and she is using her experience to help raise awareness through the Life DisRPted campaign.

    • What is the objective of the Life DisRPted campaign launched by Kiniksa Pharmaceuticals?

      The Life DisRPted campaign aims to empower patients and caregivers to recognize signs of recurrent pericarditis and to advocate for better treatment options.

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cole G Bradley converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 34% to 12,546 units (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      6/5/25 5:07:41 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Bros. Advisors Lp was granted 16,794 units of Class A Ordinary Shares (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      6/5/25 5:06:51 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levy Richard S converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 22% to 17,373 units (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      6/5/25 5:05:51 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

      – KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today– LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced details for its planned Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, expected to initiate in the middle of 2025. KPL-387 i

      6/5/25 7:00:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

      LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global Healthcare Conference on Thursday, June 5 at 12:50 p.m. Eastern TimeGoldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10 at 8:00 a.m. Eastern Time – Fireside Chat A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceuti

      5/29/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

      – Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed – LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, has partnered with Country Music Association, Academy of Country Music, and GRAMMY Award-winning country star, Carly Pearce, to share her personal experience with recurrent

      4/30/25 8:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    SEC Filings

    See more
    • Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

      6/5/25 7:10:35 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      6/3/25 4:36:06 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

      6/3/25 4:30:39 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Financials

    Live finance-specific insights

    See more
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren's Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and c

      2/25/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:32:31 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:15:22 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/13/24 4:30:25 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      3/13/25 7:43:42 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      9/13/24 7:34:05 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $34.00

      5/3/24 11:21:30 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care